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Chronic methamphetamine abuse commonly leads to psychosis, with positive and
cognitive symptoms that are similar to those of schizophrenia. Methamphetamine induced
psychosis (MAP) can persist and diagnoses of MAP often change to a diagnosis
of schizophrenia over time. Studies in schizophrenia have found much evidence of
cortical GABAergic dysfunction. Methamphetamine psychosis is a well studied model
for schizophrenia, however there is little research on the effects of methamphetamine
on cortical GABAergic function in the model, and the neurobiology of MAP is unknown.
This paper reviews the effects of methamphetamine on dopaminergic pathways, with
focus on its ability to increase glutamate release in the cortex. Excess cortical glutamate
would likely damage GABAergic interneurons, and evidence of this disturbance as a result
of methamphetamine treatment will be discussed. We propose that cortical GABAergic
interneurons are particularly vulnerable to glutamate overflow as a result of subcellular
location of NMDA receptors on interneurons in the cortex. Damage to cortical GABAergic
function would lead to dysregulation of cortical signals, resulting in psychosis, and further
support MAP as a model for schizophrenia.
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1. INTRODUCTION
Methamphetamine is a lipophilic compound used recreation-
ally for its ability to temporarily induce a variety of desirable
effects, including increased energy levels, positive mood, eupho-
ria, reduced appetite, weight loss, enhanced mental acuity, social,
and sexual disinhibition (Cretzmeyer et al., 2003; Green and
Halkitis, 2006; Cruickshank and Dyer, 2009).
According to the United Nations World Drug Report, between
0.3 and 1.3% of the world’s population uses amphetamine-
type stimulants (United Nations Office, 2011; Burns, 2014).
Amphetamine abuse has a multitude of repercussions, including
violence (Plüddemann et al., 2010) criminal behavior, incarcer-
ation, recidivism (Cartier et al., 2006), and the transmission of
HIV (Halkitis et al., 2001; Colfax and Guzman, 2006).
Repeated administrations, or administration of high doses
of methamphetamine, commonly leads to psychosis (Connell,
1958; Bell, 1965; Angrist and Gershon, 1970; Bell, 1973; Batki
and Harris, 2004; Curran et al., 2004), where symptoms typically
include paranoid delusions, auditory hallucinations, increased
activity, and odd speech (Connell, 1958; Bramness et al., 2012).
The prevalence of psychotic symptoms as a result of metham-
phetamine use can be difficult to determine as the diagnosis
could be confused with that of a primary psychotic disorder, or
other drug use (Weich and Pienaar, 2009; American Psychiatric
Association, 2013). Depending on the study, the prevalence of
psychosis in methamphetamine abusers ranges between 10 and
60% (Farrell et al., 2002; McKetin et al., 2006; Mahoney et al.,
2008). In Thailand, approximately 10% of admissions to psy-
chiatric facilities are attributed to methamphetamine related
psychosis (Farrell et al., 2002). An Australian study of 277
non-treatment-seeking illicit methamphetamine users with no
prior diagnosis of schizophrenia or other psychotic disorders
found that 51 (18%) had “clinically significant” psychotic symp-
toms (McKetin et al., 2006), and a U.S. study of 42 cocaine-
dependent and 43 methamphetamine-dependent individuals,
screened to exclude patients with other axis I disorders, reported
psychotic symptoms of at least some type in at least 60% of
both groups (Mahoney et al., 2008). Recreational use of metham-
phetamine has been shown to increase the risk of developing
psychotic symptoms by two to three fold (McKetin et al., 2010)
especially if larger amounts of methamphetamine is used, or use
began at a younger age (Chen et al., 2003).
Symptoms of MAP were originally thought to dissipate
within a week of methamphetamine withdrawal (Connell, 1958).
However, studies have shown that, although the large majority of
MAP symptoms resolve within 1 month (Iwanami et al., 1994;
Ujike and Sato, 2004; Deng et al., 2012), 30% of those with MAP
had symptoms persist for up to 6 months (Deng et al., 2012), and
10–28% reported persisting symptoms for more than 6 months
(Iwanami et al., 1994; Deng et al., 2012). Symptoms of MAP have
been shown to relapse after long periods of abstinence (Sato et al.,
1992; Yui et al., 1997, 1999).
The DSM-V indicates that persistent psychosis after 6 months
of abstinence from methamphetamine can constitute a diagno-
sis of schizophrenia (American Psychiatric Association, 2013).
A recent Chinese study found that 5% of patients initially diag-
nosed with MAP had their diagnosis changed to schizophrenia
in the interview conducted by the study (Deng et al., 2012).
In Thailand, a similar study found that 38.8% of abstinent
methamphetamine abusers who were initially hospitalized for
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MAP, were subsequently given a diagnosis of schizophrenia
(Kittirattanapaiboon et al., 2010).
Whether there are fewer presentations of negative symptoms
(lack of affect, social withdrawal) in MAP than schizophrenia
(Tomiyama, 1990; Panenka et al., 2013), or whether both pos-
itive and negative symptom presentations are similar in MAP
and schizophrenia (Srisurapanont et al., 2003, 2011), is still
under debate. However, there is broad consensus that the positive
symptoms of psychosis induced bymethamphetamine use are dif-
ficult to distinguish from the positive symptoms of schizophrenia
(Connell, 1958; Janowsky and Risch, 1979; Bramness et al., 2012;
Medhus et al., 2013).
Clinical similarities between MAP and schizophrenia have
long since been recognized (Connell, 1958). Various metham-
phetamine induced animal models for psychosis such as the neu-
rotoxicity model (Robinson and Becker, 1986; Machiyama, 1992;
Davidson et al., 2001; Cadet and Krasnova, 2009), the behav-
ioral sensitization model (Castner and Goldman-Rakic, 1999;
Featherstone et al., 2007), or the escalating dose-binge model
(Segal and Kuczenski, 1997, 2001), have been proposed and
debated for validity. Most relevant to this review is the metham-
phetamine sensitization model, where lower doses of repeated
methamphetamine exposure have been shown to produce behav-
ioral effects that best model psychosis by measurements such
as increased locomotion, hallucinatory behaviors in the case of
non-human primates, and deficits in pre-pulse inhibition, latent
inhibition, and other cognitive measures in a variety of animal
models (Castner and Goldman-Rakic, 1999; Kamei et al., 2006;
Featherstone et al., 2007; Nagai et al., 2007; Forrest et al., 2014).
Schizophrenia has been associated with a wide variety of
neurocognitive deficits e.g., in verbal memory, social cognition,
implicit learning, and working memory, which impair day to day
function (Green, 1996; Gold, 2004; Horan et al., 2008). Cognitive
functions such as working memory rely on coherent interaction
between interaction between interneurons and pyramidal cells,
which form local memory fields, and “sharpen” signal to noise
ratios (Goldman-Rakic, 1995). GABAergic interneurons in the
cortex shape the stimulus response properties of pyramidal cells,
and prevent aberrant firing of cortical processes (Jones, 1993).
Evidence for GABA dysfunction in schizophrenia is convincing,
and has been reviewed extensively (Goldman-Rakic, 1994; Lewis
et al., 2004; Daskalakis et al., 2007; Lewis et al., 2012).
If MAP is to be a good model for schizophrenia, it should also
exhibit similar cognitive impairments, and similar evidence of
GABA disturbances as schizophrenia. In humans, MAP presents
with similar cognitive impairments as those in schizophrenia,
such as deficits in verbal and working memory, as well as other
executive functions (Scott et al., 2007; Jacobs et al., 2008). In
animal models, cognitive impairments have been found in using
the amphetamine sensitization model in the non-human pri-
mate (Castner et al., 2005), and rodents (Nagai et al., 2007; Arai
et al., 2009). Indeed, emerging evidence that will be discussed in
this paper suggests that the cognitive deficits in MAP may also
result from a GABAergic dysfunction in the cortex, although the
mechanism for these observations are unknown.
The present paper will first describe the well characterized and
relevant nigrostriatal, mesolimbic, andmesocortical pathways, on
which methamphetamine exerts its major effects. Second, we will
review the acute effects of methamphetamine and chronic effects
of methamphetamine on these pathways. Next, studies that have
shown cortical GABAergic disturbance will be discussed. Finally,
we propose a possible vulnerability of GABAergic interneurons
in the cortex to glutamate overflow, which might explain the
GABAergic disturbance by methamphetamine that might lead to
psychosis.
2. NEUROCIRCUITRY OF THE CORTEX AND BASAL GANGLIA
Methamphetamine appears to primarily affect the dopaminergic
system. The present review will focus on the three main pathways,
namely the nigrostriatal, mesolimbic, and mesocortical pathways,
summarized in Figure 1.
The nigrostriatal pathway consists of the known direct and
indirect pathways, which control the expression and direction
of behavior to predictable stimuli or rewards (Balleine et al.,
2007; Nicola, 2007). The mesolimbic pathway is involved in
reward processing (Koob and Bloom, 1988), effort related func-
tions (Salamone et al., 2007), translation of emotions into actions
(Mogenson et al., 1980), and direction of behavior where stimuli
and rewards are less predictable (Nicola, 2007). The mesocorti-
cal pathway is involved with cognitive functions such as working
memory (Simon et al., 1980; Goldman-Rakic et al., 2004).
The majority (up to 77%) of the striatum consists of
GABAergic projection neurons (Graveland et al., 1985), that
receive topographical input from the cortex (Kemp and Powell,
1970; Alexander and Crutcher, 1990; Haber and Knutson, 2010),
and express N-methyl-D-aspartate (NMDA) receptors (Albin
et al., 1992). The projection neurons comprises two major sub-
populations. The striatonigral neurons, characterized by the
expression of D1 receptors, project to the basal ganglial out-
put nuclei, substantia nigra pars reticulata (SNr)/globus pallidus
interna (GPi) (Altar and Hauser, 1987), the starting point of
the direct pathway. The striatopallidal neurons, characterized by
the expression of D2 receptors, project to the globus pallidus
externa (GPe), and begin the indirect pathway. In the indirect
pathway, neurons in the GPe send GABAergic projections to
the subthalamic nucleus (STN), which send glutamatergic pro-
jections to activate the SNr/GPi. The SNr consists of tonically
active GABAergic neurons that project to the thalamus (Reubi
et al., 1977, 1978), and the thalamus projects via topographical
glutamatergic neurons to the cortex (Haber and Knutson, 2010).
Since the SNr GABAergic neurons are tonically active (Reubi
et al., 1977, 1978), there is normally little movement at rest, or
minimal signaling to the cortex from the thalamus. In addition,
up to 23% of striatal neurons are interneurons which have
inhibitory effects on the projection neurons (Rymar et al., 2004),
further inhibiting thalamocortical signals at rest (Reubi et al.,
1977, 1978). Cortical glutamatergic activation of either the direct
or indirect pathway primes the relevant pathway to an “upstate”
(Wilson and Kawaguchi, 1996). From this “upstate,” a small
additional increase in activation by dopamine, released from
the SNc, or a small decrease in inhibition by striatal cholinergic
interneurons, will lead to the generation of action potentials that
finally activate the primed pathway (Wilson, 1993; Tepper and
Bolam, 2004).
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FIGURE 1 | Nigrostriatal, mesocortical, and mesolimbic pathways. When
cortical neurons activate the NMDA receptors on neurons of the direct
pathway (red ) in the striatum, striatal neurons are primed to send GABA
signals to the SNr/GPi, which would inhibit the tonic GABA to the thalamus,
allow glutamate signals to fire in the cortex, and further activate cortical
neurons. The indirect pathway (blue) is primed when cortical neurons activate
the NMDA receptors on the striatal neurons that express D2 receptors, which
would send inhibitory signals to the globus pallidus externa (GPe), reduce
GABA signaling to the STN, and stimulate the SNr/GPi to enhance GABA
inhibiting of thalamocortical signaling. The mesolimbic pathway (green)
consist of dopaminergic projections from the VTA to the NAcc, which sends
inhibitory signals to the SNr/GPi. The mesocortical pathway (orange) consists
of dopaminergic projections from the VTA to the cortex, innervating both
pyramidal and non-pyramidal neurons which express D1 receptors. Reciprocal
pathways (purple) from the cortex to the VTA and NAcc provide cortical
feedback to subcortical structures. CTX, cortex; GABA, gamma-aminobutyric
acid; NMDA, N-methyl-D-aspartate; GPe, globus pallidus externa; SNr,
substantia nigra pars reticulata; GPi, globus pallidus interna; TH, thalamus;
STN, sub thalamic nucleus; NAcc, nucleus accumbens core; VTA, ventral
tegmental area. Round structures indicate dopamine cell bodies; star shaped
structures indicate GABA cell bodies; triangular structures indicate glutamate
cell bodies.
Activation of the dopamine system enhances glutamate signal-
ing in the cortex from the nigrostriatal and mesolimbic pathways,
and increases dopamine in the prefrontal cortex from the meso-
cortical pathway (Figure 2).
Dopamine causes activation of neurons expressing D1 recep-
tors, and inhibits neurons which express D2 receptors (Surmeier
et al., 2007). In the nigrostriatal pathway, the synergistic activa-
tion of both the D1 and D2 receptors allows dopamine to enhance
glutamate induced firing in the striatum (Hu and White, 1997).
Thus, dopamine release into the striatum from the SNc enhances
thalamocortical signals by simultaneously activating the direct
pathway, and inhibiting the indirect pathway. Long term poten-
tiation from this glutamatergic transmission leads to learning of
the relevant activity, and the development of persistent behaviors
(Yin and Knowlton, 2006; Balleine et al., 2007).
The mesolimbic pathway arises from dopaminergic ventral
tegmental area (VTA) projections to the nucleus accumbens
(NAc) (Fallon and Moore, 1978). The efferent projections of
the NAc and afferent connections with other neuronal struc-
tures such as the amygdala, hippocampus and cortex are complex,
and mediate its role in direction of behavior to emotive stim-
uli (Haber and McFarland, 1999; Haber and Knutson, 2010).
Briefly, the NAc consists of “core” and “shell” regions, and one
of the major effects of dopamine release at the NAc core is to
increase GABA release to the SNr/GPi, disinhibiting the thalamus
and increasing cortical glutamate (Maurice et al., 1999; Nicola,
2007).
The VTA and SN project to the cortex along the mesocortical
pathway, and terminates on both pyramidal and non-pyramidal
cells in the pre-frontal cortex (PFC) (Goldman-Rakic et al., 1989;
Williams and Goldman-Rakic, 1998; Tzschentke, 2001). The
expression of D1 receptors is higher than that of D2 in the cortex
(Gaspar et al., 1995), and although more prevalent on pyramidal
neurons, D1 receptors are also widely expressed on GABAergic
interneurons (Muly et al., 1998). Dopamine in the PFC serves a
modulatory purpose and enhances D1 associated firing (Cepeda
and Levine, 1998). Optimal levels of dopamine stimulates corti-
cal GABAergic interneurons, which “tune” the pyramidal firing to
sharpen pyramidal signals and enhances cognitive performance
(Muly et al., 1998).
Cortical interneurons are predominantly GABAergic and pre-
vent aberrant firing of cortical processes by shaping the recep-
tive fields of thalamocorical signals (Jones, 1993). In addition,
interneurons facilitate feed-forward inhibition, where a single
thamalmic fiber can activate its pyramidal target as well as
an interneuron, which will inhibit the pyramidal target within
1–10ms, providing fine temporal control of pyramidal firing
(Gabernet et al., 2005). These cells are necessary for inhibitory
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FIGURE 2 | Healthy effects of dopamine on dopaminergic pathways. The
substantia nigra pars compacta (SNc) releases dopamine into the striatum
(large black arrows), and enhances thalamocortical glutamate release along
the nigrostriatal pathway (blue and red ). The direct pathway (red ) becomes
enhanced by D1 activation, and the indirect pathway (blue) becomes inhibited
by D2 activation. Mesolimbic dopamine (green) to the NAc core increases
GABA inhibition from the NAc core to the SNr/GPi, further increasing
thalamocortical glutamate transmission. Mesocortical dopamine (orange)
increases cortical pyramidal firing and simultaneously stimulates cortical
interneurons, which sharpen the pyramidal signals to subcortical nuclei (blue,
red, and purple). CTX, cortex; GABA, gamma-aminobutyric acid; NMDA,
N-methyl-D-aspartate; GPe, globus pallidus externa; SNr, substantia nigra
pars reticulata; GPi, globus pallidus interna; TH, thalamus; STN, sub thalamic
nucleus; NAcc, nucleus accumbens core; VTA, ventral tegmental area. Round
structures indicate dopamine cell bodies; star shaped structures indicate
GABA cell bodies; triangular structures indicate glutamate cell bodies.
modulation, disinhibitory modulation, discriminative process-
ing, gating of signals, as well as contribute in the generation of
oscillatory rhythms that unify pyramidal cell discharge (Benes
and Berretta, 2001).
3. ACUTE EFFECTS OF METHAMPHETAMINE
Acute methamphetamine administration causes vesicular release
of dopamine from the VTA into the NAc and PFC in themesolim-
bic and mesocortical pathways (Fallon and Moore, 1978; Haber
and Knutson, 2010). Methamphetamine also reverses both vesic-
ular monoamine transporter 2 and the dopamine transporter
(Sulzer et al., 1995; Sora et al., 2009) to effectively increase synap-
tic concentrations of dopamine in the striatum in the nigrostriatal
pathway (Bustamante et al., 2002; Fowler et al., 2008; Haber and
Knutson, 2010) (Figure 3).
Acutely, methamphetamine increases levels of glutamate in the
striatum (Stephans and Yamamoto, 1994) and the PFC (Stephans
and Yamamoto, 1995). This is achieved via a polysynaptic process,
where the increased dopamine release activates gamma-aminobu-
tyric acid (GABA) neurons in the striatum of the direct pathway
and increases GABA release at their terminals in the SNr. Pre-
synaptic D1 receptors on the striatonigral terminals (Altar and
Hauser, 1987) also enhance GABA release at the SNr (Mark
et al., 2004). The increased GABA at the SNr cell bodies dis-
inhibit the thalamocortical glutamatergic pathway (Mark et al.,
2004), which results in an increase of glutamate within the cortex
(Timmerman and Westerink, 1997). The high levels of glutamate
at the level of the cortex activates the glutamatergic corticostriatal
neurons via topographically specific postsynaptic density connec-
tions (Gerfen, 1989; Bellomo et al., 1998), and increases glutamate
release in the striatum (Stephans and Yamamoto, 1994), driving
positive feedback.
Glutamate levels in the striatum in fact remain elevated for
over 28 h, even after dopamine has returned to basal levels (Mark
et al., 2004, 2007). It was found that the vesicular glutamate trans-
porter 1 expression was increased, which allows for the seques-
tration of glutamate in the cortex, and thus allowing extended
glutamate release into the striatum after methamphetamine
administration (Mark et al., 2007). The NMDA receptors in
the striatum facilitate D1 receptor mediated currents, which
positively drives this circuit.
Acute methamphetamine administration has been found to
decrease GABAB transmission within the VTA (Padgett et al.,
2012), and increases dopamine release from the VTA to the
NAc (Fallon and Moore, 1978; Kankaanpää et al., 1998; Zhang
et al., 2001). This release of dopamine in the mesolimbic path-
way is associated with the experience of reward or euphoria
(Volkow et al., 1996; Drevets et al., 2001), and increases subse-
quent GABA release to the substantia nigra for longer than 80min
(Sirinathsinghji et al., 1988). Inhibition of the SNr disinhibits the
thalamocortical glutamatergic pathway, and results in increased
cortical glutamate (Mark et al., 2004).
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FIGURE 3 | Methamphetamine effects on dopaminergic pathways.
Methamphetamine causes excessive amounts of dopamine to be released
from the substantia nigra pars compacta (SNc) into the striatum (large
black arrows), forcing pronounced inhibition of the SNr/GPi (red and blue).
Dopamine from the VTA to the NAc increases NAc inhibition on the
SNr/GPi (green). Enhanced cortical signals increases glutamate from the
PFC to the NAc (purple) further increasing NAc inhibition on the SNr/GPi,
and exacerbates glutamate excess in the cortex. CTX, cortex; GABA,
gamma-aminobutyric acid; NMDA, N-methyl-D-aspartate; GPe, globus
pallidus externa; SNr, substantia nigra pars reticulata; GPi, globus pallidus
interna; TH, thalamus; STN, sub thalamic nucleus; NAcc, nucleus
accumbens core; VTA, ventral tegmental area. Round structures indicate
dopamine cell bodies; star shaped structures indicate GABA cell bodies;
triangular structures indicate glutamate cell bodies.
Methamphetamine also increases dopamine release from the
VTA to the prefrontal cortex in the mesocortical pathway (Fallon
and Moore, 1978; Stephans and Yamamoto, 1995). At low doses,
methamphetamine can increase cognitive performance by activa-
tion of D1 receptors in the PFC (Silber et al., 2006), however high
doses impair cognitive function (Schroder et al., 2003), possibly
by over activation of D1 receptors on interneurons in the PFC
and excessive inhibition of cortical signals (Muly et al., 1998).
Methamphetamine can thus increase glutamatergic signals to
the cortex from both the nigrostriatal, as well as the mesolim-
bic reward circuits, and increase dopaminergic signals from the
mesocortical pathway. Excessive glutamate and dopamine in the
cortex may overwhelm GABAergic interneuons, causing dysregu-
lation of the signals, which may relate to the psychotic symptoms
that can occur during methamphetamine intoxication in some
individuals.
4. CHRONIC METHAMPHETAMINE EFFECTS
Studies in chronic methamphetamine abusers have found sev-
eral changes in the brain, particularly within the striatum. A post
mortem study found decreased levels of dopamine terminal
markers such as dopamine, tyrosine hydroxylase, and dopamine
transporter in the striatum (Wilson et al., 1996). Positron emis-
sion tomography research found decreased levels of the dopamine
transporter (Volkow et al., 2001b), decreased D2 (Volkow et al.,
2001a) and decreased vesicular monoamine transporter 2 in the
striatum (Chang et al., 2007). Single photon emission computed
tomography studies have found decreased regional cerebral blood
flow in chronic methamphetamine abusers (Iyo et al., 1997;
Chung et al., 2010), magnetic resonance spectroscopy found
decreased N-acetylaspartate (NAA) in the basal ganglia and
frontal lobe (Ernst et al., 2000; Howells et al., 2014), and anterior
cingulate (Nordahl et al., 2002; Howells et al., 2014) indicative of
decreased neuronal integrity in these areas.
Participants with MAP have shown decreased P300 ampli-
tude and increased P300 latency, particularly over the frontal
cortex in electroencephalography (EEG) event related potential
(ERP) studies, which suggests dysfunctional higher cognitive pro-
cessing (Iwanami et al., 1991, 1993, 1998). Magnetic resonance
spectroscopy showed decreased creatine and phosphocreatine to
choline (Cr+PCr/Cho) ratio in the basal ganglia that correlated
significantly with increased residual psychiatric symptom severity
(Sekine et al., 2002). Magnetic resonance imaging processed for
voxel based morphometry found decreased frontopolar volumes
compared to healthy controls (Aoki et al., 2013).
Various regimen of methamphetamine administration have
developed different models for MAP and schizophrenia. The neu-
rotoxicity model typically gave high doses of methamphetamine
in a short amount of time, and found extensive neurotoxic dam-
age, particularly to the nigrostriatal and mesolimbic systems
(Robinson and Becker, 1986; Machiyama, 1992; Davidson et al.,
2001; Cadet and Krasnova, 2009). However, it has been argued
that the severe neurotoxicity produced by this model is not sim-
ilar to the lack of obvious neurotoxic damage in people with
MAP and schizophrenia, in addition methamphetamine abusers
tend to begin with low doses of methamphetamine, which have
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shown to be neuroprotective to subsequent higher doses. Most
relevant to this review is the methamphetamine sensitization
model, where lower doses of repeated methamphetamine expo-
sure have been shown to produce behavioral effects that best
model psychosis by measurements such as increased locomotion,
hallucinatory behaviors in the case of non-human primates, pre-
pulse inhibition deficits, latent inhibition deficits, other cognitive
deficits (Castner and Goldman-Rakic, 1999; Castner et al., 2000;
Kamei et al., 2006; Featherstone et al., 2007; Nagai et al., 2007;
Forrest et al., 2014). Although, the escalating dose-binge model
also appears to model a widely used pattern of drug taking by
abusers (Segal and Kuczenski, 1997, 2001).
Methamphetamine sensitized animals showed increased glu-
tamate levels in the VTA 3 days after withdrawal (Giorgetti
et al., 2002). The enhanced VTA activation increased release of
dopamine in the NAc (Gonon, 1988) and dorsal striatum with
a low dose amphetamine challenge after 28 days of withdrawal
(Paulson and Robinson, 1995). Glutamate release was found to
be increased in the NAc 2 days post withdrawal with low dose
amphetamine challenge (Xue et al., 1996), or with K+ depolar-
ization 1 day post withdrawal (Bustamante et al., 2002). Studies
in addiction have found that the increased sensitivity of the NAc
to glutamate, and the increased glutamate release from the PFC to
theNAc,mediates craving, and relapse in response to drug-related
cues (Cornish and Kalivas, 2000; Kalivas and Volkow, 2005).
Hyper-sensitivity of the NAc would further increase the acti-
vation of the NAc-thalamocortical circuit, and increase cortical
glutamate (Maurice et al., 1999; Nicola, 2007).
Methamphetamine withdrawal after sensitization also exag-
gerated the inhibitory responses in the medial PFC, while
augmenting excitatory responses in the ocular frontal cortex
(Homayoun andMoghaddam, 2006).Morphological studies have
found increased dendritic branching in the NAc and PFC of
rodents approximately 1 month after methamphetamine sensi-
tization (Robinson and Kolb, 1997, 1999), while a study in the
dorsolateral PFC of non-human primates found decreased den-
dritic length and branching approximately 3 years after metham-
phetamine sensitization (Selemon et al., 2007). Twelve weeks
of repeated low dose amphetamine exposure in rhesus mon-
keys showed reduced [123]IBZM displacement, and thus reduced
dopamine release, in the striatum in response to a low dose
amphetamine challenge about 30 days post withdrawal (Castner
et al., 2000). Work on non-human primates has also shown
that the cognitive deficits produced by methamphetamine sen-
sitization are related to reduced dopaminergic turnover in the
PFC and striatum (Castner et al., 2005), mediated by the D1-
ERK pathway dysfunction in the PFC (Nagai and Yamada,
2010).
While studies in the methamphetamine sensitization model of
psychosis is extensive (Featherstone et al., 2007), few have exam-
ined the effects of chronic methamphetamine exposure on the
cortical GABAergic system.
5. CHRONIC METHAMPHETAMINE EFFECTS ON CORTICAL
GABA
Little research using any model has studied methamphetamine
effects on GABA in the cortex, however there is some evidence
which indicates that methamphetamine may indeed cause
damage to cortical GABAergic interneurons.
Postmortem staining of the cortex in HIV positive metham-
phetamine users, compared to HIV positive non-users found
extensive loss of calbindin immunoreactive interneurons in the
cortex (Langford et al., 2003). Although co-morbid HIV and
methamphetamine is known to compound neurodegenerative
effects (Liu et al., 2009; Reiner et al., 2009), another group
also found decreased calbindin immunoreactivity in cortical
interneurons in rats that underwent an escalating dose, multiple
binge exposure to methamphetamine, without the HIV confound
(Kuczenski et al., 2007).
The escalating dose, multiple binge exposure of metham-
phetamine to the rats (0.1mg/kg escalated in 0.1mg/kg incre-
ments 3 times a day, to 4mg/kg over 14 days, then 4 injections of
6mg/kg every 2 h for 11 successive days) in the Kuczenski et al.
(2007) study deserves further discussion. The loss of calbindin
immunoreactive interneurons was apparent from 3 days after
last exposure to methamphetamine, and persisted when exam-
ined at 30 days post exposure. Pyramidal neurons and dendrites
(marked by NeuN and MAP2 staining, respectively), were not
significantly lost at 3 days post exposure, but were significantly
reduced at 30 days post exposure, particularly in layers 2, 3, and
5 (Kuczenski et al., 2007). These results suggest a particular vul-
nerability of interneurons to methamphetamine administration,
as compared to pyramidal neurons. The contrary observation
of loss of pyramidal cells and dendrites in this study and the
increased dendritic branching and spine densities in the PFC and
NAc as seen in earlier studies (Robinson and Kolb, 1997, 1999)
was not discussed. The Kuczenski study appears to be supported
by the morphological study in non-human primates that showed
decreased dendritic branching in the dorsolateral PFC 3 years post
amphetamine sensitization (Selemon et al., 2007). Selemon et al.
explained possible discrepancies between the primate study and
Robinson’s studies to species differences or interval of metham-
phetamine discontinuation, however the two rodent studies were
both performed in Sprague-Dawley rats, and examined at 30
(Kuczenski et al., 2007) or 38 (Robinson and Kolb, 1997, 1999)
days post exposure. In addition, the methamphetamine adminis-
tration regimen was similar, where the Robinson and Kolb study
escalated doses of D-amphetamine from 1 to 8mg/kg for 5 weeks
excluding weekends, and gave 8mg/kg doses twice a day, 4 h apart
for the last 4 days (Robinson and Kolb, 1997). Further work
regarding methamphetamine effects on cortical morphometry
may be helpful to clarify these discrepancies.
A toxicity study delivered a continuous high dose
(32mg/kg/day) of methamphetamine by implanted minipump in
rats for 5 days (Armstrong and Noguchi, 2004). Autoradiography
of GABAA sites labeled with [3H]-Flunitrazepam showed that
methamphetamine treatment caused a significant general
decrease in staining on the entire hemi-brain, and significant
decrease in the hippocampus. Other areas that were compared
did not show significant decreases compared to drug naïve
rats, although there was a general pattern of lower GABA
binding in anterior cingulate, caudate, NAc, thalamus, and
amygdala (Armstrong and Noguchi, 2004). Perhaps an increase
in sample size to more than 8 rats in controls, and 7 rats in the
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methamphetamine treated group may have shown significant
decreased [3H]-Flunitrazepam binding in these areas.
More recent studies have found that methamphetamine sensi-
tization in mice (4 injections of 2mg/kg, every other day) caused
memory impairment, and autoradiography showed decreased
[3H]MK-801 binding to NMDA receptors in the cortex, and
hippocampus (Lee et al., 2011). Whether NMDA receptors that
were lost were expressed on pyramidal or non-pyramidal neu-
rons within the PFC is unclear, and the interval between last
methamphetamine exposure and autoradiography was only 24 h,
immediately after the passive avoidance test (Lee et al., 2011).
A different mouse sensitization study (1mg/kg every day for
7 days) produced cognitive deficits that were ameliorated by
the GABAB receptor agonist baclofen (1–2mg/kg acute dose)
(Arai et al., 2009). Baclofen has also been shown to ameliorate
methamphetamine induced pre-pulse inhibiton and object recog-
nition memory deficits in mice (Mizoguchi and Yamada, 2011).
Amphetamine induced dopamine release in the PFC is reduced
by baclofen and SKF97541, which activate presynaptic GABAB
receptors on dopamine terminals (Balla et al., 2009).
A recent magnetic resonance spectroscopy study in metham-
phetamine sensitized rat brain dissections (2.5mg/kg twice per
day over 7 days) showed decreased GABA, glutamate, and
glutamine levels in the PFC (Bu et al., 2013). Acute metham-
phetamine administration showed the ability to sequester gluta-
mate in the cortex for over 28 h through upregulation of VGLUT1
(Mark et al., 2007). The Bu et al. study sacrificed the animals
within 30min of the last dose of methamphetamine and one
might have expected to find increased glutamate levels in the pre-
frontal cortex. However, these authors suggest that the reduction
in glutamate is likely due to higher demand, while the reduction
in GABA was thought to be due both reduced glutamate as a sub-
strate to form GABA, as well as increased GABA metabolism to
succinic acid semialdehyde (which was found to be increased) (Bu
et al., 2013).
Even though there is vast methodological variation in the
above studies, each have shown evidence of cortical GABAergic
deficit as a result of methamphetamine treatment. Damage to
cortical GABAergic function could account for the cognitive
impairments and persistent psychosis symptoms in MAP. The
mechanism for this deficit is unknown. The present review pro-
poses that there may be particular vulnerability of GABAergic
interneurons, that might contribute to these observations of
GABA dysfunction in the cortex as a result of methamphetamine
exposure.
6. CORTICAL GABAergic INTERNEURON VULNERABILITY
TheNMDA receptor is an ionotropic glutamate receptor that con-
sists of a heterotetramer of two NR1 and two NR2 subunits, and
mediates excitatory post-synaptic potentials (Dingledine et al.,
1999). NMDA receptors are distributed widely throughout the
nervous system (Petralia et al., 1994b).
The downstream effect of NMDA receptor function is highly
dependent on the location of the receptors. The expression of
N-methyl-D-aspartate (NMDA) receptors on postsynaptic pyra-
midal neurons leads to activation of the glutamatergic system
and downstream neuronal activation. The expression of NMDA
receptors on GABAergic interneurons results in a release of
GABA, and has a downstream inhibitory effect. Thus, activation
of NMDA receptors on pyramidal neurons leads to further release
of glutamate, thereby providing positive feedback; while activa-
tion of NMDA receptors on interneurons leads to GABA release
and regulation of glutamatergic function.
Pyramidal neurons in the cortex primarily express NMDA
receptors at the somatic membrane, and proximal dendrites and
in post synaptic densities (Aoki et al., 1994; Petralia et al., 1994a),
with decreased expression at more distal dendrites (Huntley et al.,
1994). Cortical GABAergic interneurons have typically multipo-
lar aspiny dendrites (Kawaguchi, 1995; DeFelipe, 2001), with the
majority of NMDA receptors expressed on the dendrites, not
close to obvious post synaptic densities (Goldberg et al., 2003a,b)
(Figure 4). Dense patterns of NMDAR1 staining appear particu-
larly in the neuropil of layer II and III in the cortex (Aoki et al.,
1994; Huntley et al., 1994), which coincide with the dense den-
dritic projections of basket, chandelier, and double bouquet type
interneurons in this region (Benes and Berretta, 2001; DeFelipe,
2001; Gentet, 2012). Discussions of the various types, morphol-
ogy, and physiological characterizations of GABAergic interneu-
rons are interesting but not within the scope of this paper, and
have been have been thoroughly reviewed elsewhere (Benes and
Berretta, 2001; DeFelipe, 2001; Gentet, 2012).
The predominance of synaptic NMDA receptors on the
pyramidal neurons, and extrasynaptic NMDA receptors on
GABAergic interneurons differentiates their vulnerability to
neurotoxicity (Papadia and Hardingham, 2007). Synaptic and
extrasynaptic NMDA receptors have opposite effects regard-
ing cAMP response element binding protein (CREB) function,
gene regulation, and neuron survival (Hardingham et al., 2002).
Calcium ion entry through synaptic NMDA receptors induces
CREB activity and brain derived neurotrophic factor (BDNF)
gene expression as strongly as those caused by direct stimula-
tion of L-type calcium channels. In contrast, calcium ion entry
FIGURE 4 | NMDA receptor localization in the cortex. (A) Glutamatergic
pyramidal neurons express NMDAreceptors preferentially in the post
synaptic density (PSD) region, around the soma, and apical dendrites.
Glutamate stimulation causes more focused calcium ion influx, and the cell
has lower vulnerability to neurotoxicity (B) GABAergic interneurons express
NMDA receptors more diffusely over the neuron, often at extrasynaptic
locations. Glutamate stimulation causes widespread calcium ion influx, and
the cell has greater vulnerability to neurotoxicity.
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FIGURE 5 | Summary flow diagram.
through extrasynaptic NMDA receptors, triggered by bath glu-
tamate exposure or hypoxic conditions, activates a dominant
pathway that blocks CREB and thus BDNF expression. In essence,
synaptic NMDA receptors, mostly localized on glutamatergic
cells, have anti-apoptotic activity, whereas stimulation of extrasy-
naptic NMDA receptors on interneurons results in glutamate-
induced excitotoxicity (Hardingham et al., 2002). Similar CREB
inhibiting effects have been found by activation of extrasynap-
tic NMDA receptors in co-cultured cortical glutamatergic and
striatal GABAergic neurons, while synaptic NMDA activation on
GABAergic striatal neurons was neuroprotective (Kaufman et al.,
2012). Details of the mechanisms of the dicotomous effects of
synaptic vs. extrasynaptic NMDA receptor activation is reviewed
elsewhere (Papadia and Hardingham, 2007; Hardingham and
Bading, 2010). Essentially, lower levels and specific activation of
synaptic NMDA receptors promote neuroprotection and inhibits
apoptotic pathways; while bath stimulation or over spill from
high level stimulation cause extrasynaptic NMDA receptor acti-
vation, which not only inhibits CREB and BDNF expression, but
also promotes a variety of other pro-death cascades (Papadia
and Hardingham, 2007; Hardingham and Bading, 2010; Petralia,
2012).
Activation of predominantly extrasynaptic NMDA recep-
tors on GABAergic interneurons would make these cells more
vulnerable to neurotoxicity than pyramidal neurons. Thus, per-
sistent glutamate overflow from the overstimulated thalamus and
NAc to the cortex from repeated methamphetamine administra-
tion might lead to accelerated damage to interneurons compared
to pyramidal neurons. Indeed, an escalating dose multiple binge
regimen of methamphetamine administration in rats found that
calbindin stained cortical interneurons were more sensitive to
methamphetamine toxicity than their NeuN stained pyramidal
neurons, as the interneurons were significantly lost from 3 days
after the last methamphetamine binge dose, whereas the pyrami-
dal neurons were lost only 30 days after the last dose (Kuczenski
et al., 2007). Damage to cortical interneurons would diminish the
negative feedback on pyramidal neurons, and result in increased
subsequent pyramidal firing.
Cortical GABAergic interneurons synchronize cortical pro-
cesses (Jones, 1993; Benes and Berretta, 2001). Damage to these
neurons, whether by methamphetamine induced neurotoxicity,
developmental defect, or other mechanisms would dysregulate
glutamate signaling in the cortex. Even transient inhibition of
NMDA receptors by a dose of MK-801 that impaired work-
ing memory in rats decreased organized bursting activity and
increased the number of irregularly discharged single spikes from
prefrontal pyramidal neurons (Jackson et al., 2004). Aberrant
glutamate signals transmitted through the cortico-striatal-
thalamo-cortical loop may result in aberrant behaviors, and
psychosis.
7. SUMMARY
The development of MAP might ultimately be due to damage
of cortical interneurons. Cortical interneurons are likely more
vulnerable to neurotoxicity, as they have a higher proportion of
extrasynaptically expressed NMDA receptors. Methamphetamine
use causes an overflow of dopamine in the striatum, which leads
to excessive glutamate release into the cortex. Excess glutamate in
the cortex might, over time, cause damage to cortical interneu-
rons. Damage to cortical interneurons dysregulate thalamocor-
tical signals, and might result in the presentation of psychotic
symptoms as seen in schizophrenia (Figure 5).
Studies of GABAergic disturbance in the cortex as a result of
methamphetamine have been presented, however further stud-
ies that directly compare cell type vulnerabilities to synaptic or
extrasynaptic stimulation, as well as measurements of GABA con-
centrations, receptor expression and sensitivity in the cortex as a
result of methamphetamine sensitization or psychosis, would be
required to test this hypothesis.
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